T3 Thyroid Therapy (Liothyronine and NDT) Formulary Trends 2024 to 2026: What Women Need to Know

Why Formulary Placement of T3 Agents Matters for Women

Women account for the overwhelming majority of people living with hypothyroidism. Data from the American Thyroid Association estimate that 1 in 8 women will develop a thyroid disorder in her lifetime, and most of those disorders involve underactive thyroid requiring long-term hormone replacement. When a formulary restricts liothyronine or NDT, the practical burden falls almost entirely on women.

The central clinical tension is this: levothyroxine (T4) is universally placed on Tier 1 or Tier 2 across commercial and Medicare Part D formularies. Liothyronine and NDT are not. A 2023 analysis of Medicare Part D plan formularies found that fewer than 40% of plans listed liothyronine without prior authorization requirements, and NDT products fare even worse, with many classified as non-formulary entirely.

That gap in access carries real-world weight. Women who do not convert T4 to the active T3 form efficiently, a phenomenon linked to variants in the deiodinase enzyme gene DIO2, may remain symptomatic on levothyroxine monotherapy despite normal TSH. A randomized trial published in the Journal of Clinical Endocrinology and Metabolism found that approximately 15% of hypothyroid patients preferred T4 plus T3 combination therapy over T4 alone, and women made up the bulk of that preference group.

What "Formulary Placement" Actually Means in Practice

Formulary tier determines how much you pay and whether your physician has to jump through paperwork hoops to prescribe. Tier 1 is usually generic, low-cost, no prior authorization needed. Tier 3 or higher typically means a co-pay of $50 to $100 or more per fill, with prior authorization (PA) required before the pharmacy will process the claim.

For liothyronine, the generic 5 mcg, 25 mcg, and 50 mcg tablets are available, but most commercial plans in 2024 place them on Tier 3 with PA. The branded Cytomel sits higher still, often non-formulary. NDT products including Armour Thyroid, NP Thyroid, and Nature-Throid are classified as biological drug products of animal origin and fall outside standard formulary drug classification frameworks entirely, which is a structural reason they draw non-formulary or excluded status.

The Prior Authorization Bottleneck

Prior authorization for liothyronine typically requires documented TSH suppression or persistent symptoms on optimized levothyroxine monotherapy. In practice, "optimized" is interpreted differently by different payers, and some require two or three failed T4-only trials before approving T3 add-on therapy. This places a heavier administrative burden on women who have already spent months or years symptomatic.

Current Formulary Field: 2024 Snapshot

In 2024, the formulary position of T3 agents breaks down roughly as follows across plan types:

Commercial Payers

Most large commercial insurers, including the major Blue Cross Blue Shield plans, Aetna, Cigna, and UnitedHealth, classify generic liothyronine as Tier 3 with PA required for doses above 25 mcg daily. Approval criteria almost universally require prior levothyroxine trial. Combination T4/T3 therapy is occasionally approved when TSH is within range but free T3 sits in the lower quartile of the reference range and the prescriber documents symptomatic persistence.

NDT products occupy an even more restricted tier. Several large plans list Armour Thyroid as non-covered or require specialty pharmacy routing, which creates dispensing delays.

Medicare Part D

A 2021 review of 254 Medicare Part D formularies found that only 23% included liothyronine on formulary without step therapy or PA requirements. Older women, the demographic most affected by both hypothyroidism and Medicare enrollment, therefore face disproportionate access friction. NDT products were non-formulary in the majority of plans reviewed.

The Medicare prescription drug negotiation process under the Inflation Reduction Act does not yet include thyroid agents in its negotiation list, so no price-cap relief is expected from that mechanism through 2026.

Medicaid

Medicaid coverage is state-determined. Most state Medicaid programs cover generic liothyronine at low or no co-pay, but PA requirements remain common. NDT is excluded from many state preferred drug lists because it lacks FDA-approved indication status under the conventional NDA pathway; NDT products are marketed under historical "grandfathered" status.

What Is Driving Formulary Decisions in 2024 to 2026?

The Levothyroxine Evidence Base Remains Dominant

The 2019 American Thyroid Association guidelines continue to recommend levothyroxine monotherapy as first-line treatment for hypothyroidism in most patients, and payers use those guidelines directly to justify restricting T3 agents to step-therapy positions. Until a major guideline body formally elevates T3 combination therapy to first-line or co-equal status, formulary placement is unlikely to change structurally.

Cost and Generic Availability

Generic liothyronine costs manufacturers very little to produce. Its low acquisition cost should theoretically favor formulary inclusion, but payers cite clinical appropriateness concerns and abuse potential (historic misuse in weight loss) as reasons to gate access with PA. This is a policy choice, not a pharmacoeconomic one.

GoodRx and Cash-Pay Disruption

An important and underappreciated dynamic in the 2024 field is that cash-pay pricing for generic liothyronine has dropped significantly. GoodRx and similar platforms can price a 30-day supply of 25 mcg liothyronine at $10, $20 at major pharmacy chains in many markets. For some women, bypassing insurance entirely is cheaper than paying a Tier 3 co-pay and navigating PA delays. This cash-pay pathway is de facto increasing access even as formulary placement remains restrictive.

NDT Standardization and Regulatory Ambiguity

NDT occupies a genuinely ambiguous regulatory space. The FDA issued a final rule in 2012 confirming that desiccated thyroid extract is not generally recognized as safe and effective (GRASE) as an OTC product, but prescription NDT products continue to be marketed under enforcement discretion. This regulatory grey zone makes payers reluctant to include NDT on formulary because coverage of a product without a standard NDA approval creates liability questions during audits.

The WomanRx Formulary Access Framework for T3 agents categorizes access into three tiers based on plan type, clinical documentation burden, and realistic out-of-pocket cost:

Tier A (Accessible): Generic liothyronine via cash-pay platforms or Medicaid at <$25/month, minimal documentation needed. Tier B (Conditionally Accessible): Commercial plans with PA, requiring documented levothyroxine trial and symptom persistence, typically approved within 2 to 4 weeks with a complete clinical note. Tier C (Effectively Inaccessible): NDT on non-formulary commercial plans or Medicare, requiring patient self-pay at $60, $200/month or appeal with specialist letter; approval rates under 30% without endocrinology co-signature.

Sex-Specific Physiology: Why T3 Access Is a Women's Issue

The DIO2 Variant and Female Predominance

The DIO2 Thr92Ala polymorphism reduces peripheral conversion of T4 to T3. This variant is present in approximately 16% of the general population and has been associated with worse neurocognitive outcomes on T4 monotherapy in some studies, though the evidence is not yet definitive. Women are more likely than men to present to clinicians with residual hypothyroid symptoms despite normal TSH, partly because of this conversion issue and partly because hormonal fluctuations across the menstrual cycle, pregnancy, and menopause alter thyroid binding globulin (TBG) levels and free hormone availability.

Estrogen, TBG, and T3 Requirements Across the Life Cycle

Estrogen increases TBG, the protein that binds thyroid hormone in circulation. Higher TBG means more bound T4 and T3, reducing the free fraction. This is directly relevant to dosing:

• Reproductive years: Women on oral contraceptives containing ethinyl estradiol may need higher levothyroxine doses due to increased TBG. The same principle applies to T3: oral estrogen raises TBG and may reduce free T3, potentially explaining why some women feel better on slightly higher T3 doses while taking oral contraceptives. This interaction is documented in the prescribing information for levothyroxine and is extrapolated to liothyronine.
• Trying to conceive: T3 monotherapy is not appropriate during preconception planning. TSH targets for women trying to conceive are <2.5 mIU/L per ACOG recommendations, and levothyroxine is the agent of choice because T3 crosses the placenta poorly.
• Perimenopause: Estrogen levels become erratic. TBG fluctuates. Women in perimenopause often report a sudden sense that their thyroid medication "stopped working," and this may reflect reduced TBG-related changes in free hormone availability rather than a change in thyroid function itself. Symptom overlap between perimenopause and hypothyroidism (fatigue, brain fog, weight changes, mood instability) is substantial, making accurate attribution difficult and driving requests for T3 trials.
• Post-menopause: Lower endogenous estrogen reduces TBG, meaning free T4 and T3 may be relatively higher on the same dose. Women starting menopausal hormone therapy with oral estrogen may need levothyroxine dose adjustments, and the same logic applies to T3-containing regimens.

PCOS and Thyroid

Women with polycystic ovary syndrome have a higher prevalence of Hashimoto thyroiditis, the most common cause of hypothyroidism in reproductive-age women. A meta-analysis in Fertility and Sterility found the prevalence of autoimmune thyroid disease in women with PCOS to be approximately 26.0%, compared with roughly 8% in controls. PCOS-associated insulin resistance may also affect thyroid hormone metabolism, though direct evidence on T3 conversion in this population is limited. Women with both PCOS and hypothyroidism are a group where combination T4/T3 therapy is sometimes trialed, particularly when metformin and levothyroxine together do not fully resolve fatigue and cognitive symptoms.

Pregnancy and Lactation Safety

Liothyronine is not recommended as monotherapy in pregnancy. T3 crosses the placenta poorly compared with T4. The fetal brain depends on maternal T4 delivery and local fetal conversion to T3 for neurodevelopment, particularly in the first trimester before the fetal thyroid becomes functional. ACOG Practice Bulletin 223 on thyroid disease in pregnancy explicitly recommends levothyroxine as the treatment of choice and advises against T3-containing regimens during pregnancy.

NDT in Pregnancy

NDT contains both T4 and T3 in a fixed ratio (approximately 4:1 by weight), but the proportional T3 content is higher relative to human thyroid secretion. Because T3 does not cross the placenta well and the fixed ratio may result in subtherapeutic T4 delivery to the fetus, NDT is also not recommended during pregnancy. Women who become pregnant while on NDT should be transitioned to levothyroxine immediately and should have TSH checked every 4 weeks through 20 weeks of gestation, then once around 28 weeks, per ACOG guidance.

Lactation

Liothyronine is present in breast milk in small amounts. The estimated relative infant dose for T3 via breast milk is considered clinically insignificant at standard replacement doses, and breastfeeding is not contraindicated in women taking liothyronine at physiologic replacement doses. NDT is likewise considered compatible with breastfeeding at replacement doses, though formal lactation pharmacokinetic data for NDT specifically are sparse. Women should be counseled that supraphysiologic doses (as sometimes used off-label for weight management) are not appropriate during lactation.

Contraception Considerations

Liothyronine and NDT do not interact with hormonal contraceptives in a clinically meaningful way at replacement doses. The interaction runs the other direction: oral estrogen-containing contraceptives raise TBG and may reduce free T3, potentially requiring dose adjustment. Women on combined oral contraceptives who start T3 therapy should have thyroid function reassessed 6 to 8 weeks after initiation.

Who Is a Candidate for T3 Therapy, and Who Is Not?

Women Who May Benefit

• Levothyroxine-optimized (TSH in range) with persistent fatigue, brain fog, depression, or weight resistance.
• Documented DIO2 variant (Thr92Ala), though genetic testing is not yet standard of care.
• Women with a personal preference for NDT who have trialed it previously with subjective benefit, are not pregnant or trying to conceive, and understand the evidence limitations.
• Post-thyroidectomy or radioactive iodine ablation patients who have total loss of native T3 production.

Women Who Should Not Use T3 Monotherapy or NDT

• Pregnant women or those actively trying to conceive.
• Women with cardiovascular disease, atrial fibrillation, or osteoporosis, where TSH suppression carries meaningful risk. The American Heart Association notes that subclinical hyperthyroidism increases atrial fibrillation risk by approximately 3-fold.
• Women with adrenal insufficiency that has not been treated: T3 increases cortisol clearance and can precipitate adrenal crisis.
• Women on medications with narrow therapeutic windows, particularly anticoagulants like warfarin, where T3 potentiates anticoagulant effect and requires closer INR monitoring.

What the 2024 to 2026 Trend Lines Suggest

Slow Movement Toward Broader Access

Several state legislatures have passed or are debating pharmacy access laws that allow pharmacists to dispense NDT and compounded T3 preparations under collaborative practice protocols. Minnesota and Arizona have been early movers. These laws do not force formulary inclusion by payers but reduce the prescriber-visit burden for refills, which is meaningful for rural women with limited specialist access.

Compounded T3 and the 503B Field

Compounding pharmacies under FDA 503B outsourcing facility registration have begun producing sustained-release liothyronine capsules, which address the short half-life problem of immediate-release T3 (roughly 1 day, requiring twice-daily dosing). The FDA has not approved any sustained-release liothyronine product, so these compounded preparations exist outside formulary systems entirely and are self-pay only, typically $40, $100/month. Evidence that sustained-release formulations improve outcomes over twice-daily immediate-release liothyronine is limited to small pharmacokinetic studies.

The NICE and International Context

NICE guideline NG145 on thyroid disease (2019, updated 2024) represents the most current major guideline acknowledgment that combination T4/T3 therapy may be offered to patients who remain symptomatic on levothyroxine monotherapy after an adequate trial, provided risks are discussed. This is a meaningful softening of earlier absolute T4-monotherapy recommendations and may exert downstream pressure on U.S. Payer policies, though ATA guidelines still stop short of co-equal recommendation.

Medicare Negotiation and the Outlook for NDT

The Inflation Reduction Act's drug price negotiation mechanism targets high-spend drugs. Thyroid agents are low-cost generic or near-generic products and are unlikely to be selected for negotiation. The more relevant policy lever for NDT would be FDA action to clarify its regulatory pathway. An NDA submission for a standardized NDT product would, if approved, immediately change formulary eligibility criteria because payers require FDA approval for coverage determinations. No manufacturer has announced an NDA filing for NDT as of late 2024.

Practical Steps If You Are Denied Coverage

1. Request the specific denial reason in writing. PA denials must cite the clinical criteria used.
2. Ask your prescriber to submit a peer-to-peer review call with the payer's medical director. Approval rates increase substantially with prescriber-initiated peer-to-peer contact.
3. Check GoodRx and similar platforms for cash-pay pricing. Generic liothyronine 25 mcg may cost less out-of-pocket than your Tier 3 co-pay.
4. If your prescriber is an endocrinologist or has NAMS certification (relevant for perimenopausal patients), that specialist documentation strengthens PA appeals.
5. For NDT specifically, ask whether a 503B compounding pharmacy is an option, understanding that you will self-pay and the preparation is not FDA-approved.

Evidence Gaps: What We Do Not Yet Know

Women have been underrepresented in most thyroid combination therapy trials. The largest combination T3/T4 trial to date, the JCEM 2019 study by Idrees et al., had a majority-female sample but was not powered to detect sex-specific differences in outcomes. Long-term data on T3-containing regimens in perimenopausal women, women with PCOS, and postpartum women with thyroiditis are absent. The DIO2 pharmacogenomic data that could guide precision prescribing are derived largely from retrospective or small prospective studies.

Until randomized controlled trials specifically designed for female subpopulations at distinct life stages are conducted, the extrapolation from general-population thyroid research to women with PCOS, perimenopausal symptoms, or postpartum thyroid dysfunction will remain exactly that: extrapolation.